AerWave是一家疾病缓解超声肺去神经疗法开发商。AerWave的超声平台旨在简化和增强肺去神经支配过程，通过单一能量应用，平台能够提供精确的圆周消融，从而减少气道平滑肌的收缩。这一创新方法直击疾病的潜在驱动因素，而不仅仅是控制症状，为患者提供了更为根本的治疗途径。近日，AerWave成功筹集了1200万美元的资金，以进 ...
器械之家医疗器械媒体报道先锋分享专业医疗器械知识关注 来源：医械一线近日，生物医学工程领域传来一则振奋人心的消息：纽约总部的AerWave公司宣布，其疾病缓解超声肺去神经疗法已成功完成了首次人体可行性研究。这一突破性的进展为慢性阻塞性肺病（COPD） ...
A Midtown-based medical device startup is carving a niche in the growing field of treatments to address chronic lung disease.
AerWave announced today that it completed the first-in-human feasibility study of its disease-modifying ultrasound lung ...
Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...
GlobalData on MSN5 天
AerWave Medical concludes study of ultrasound therapy for COPDThe study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
AerWave Medical has concluded the feasibility study of its ultrasound lung denervation therapy, designed to treat chronic obstructive pulmonary disease (COPD) and asthma. The first-in-human study ...
08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, today announced the successful completion of its first-in-human (FIH) feasibility ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈